AbbVie announced key results from a phase 2 study of upadacitinib given as monotherapy, or in combination therapy (ABBV-599) with elsubrutinib, a kinase inhibitor...
AbbVie announced topline results from a Phase 2 study of upadacitinib given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib,...
ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinical studies in the U.S....
